Katherine H Chin1, Michael J Bell, Stephen R Wisniewski, Goundappa K Balasubramani, Patrick M Kochanek, Sue R Beers, S Danielle Brown, P David Adelson. 1. 1Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 2Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA. 3Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA 4Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 5Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA. 6Barrow Neurological Institute of Phoenix Children's Hospital, Phoenix, AZ.
Abstract
OBJECTIVE: To evaluate the association between neuromuscular blocking agents and outcome, intracranial pressure, and medical complications in children with severe traumatic brain injury. DESIGN: A secondary analysis of a randomized, controlled trial of therapeutic hypothermia. SETTING:Seventeen hospitals in the United States, Australia, and New Zealand. PATIENTS: Children (< 18 yr) with severe traumatic brain injury. INTERVENTIONS: None for this secondary analysis. MEASUREMENTS AND MAIN RESULTS: Children received neuromuscular blocking agent on the majority of days of the study (69.6%), and the modified Pediatric Intensity Level of Therapy scores (modified by removing neuromuscular blocking agent administration from the score) were increased on days when neuromuscular blocking agents were used (9.67 ± 0.21 vs 5.48 ± 0.26; p < 0.001). Children were stratified into groups based on exposure to neuromuscular blocking agents (group 1 received neuromuscular blocking agents each study day; group 2 did not). Group 1 had increased number of daily intracranial pressure readings more than 20 mm Hg (4.4 ± 1.1 vs 2.4 ± 0.5;p = 0.015) and longer ICU and hospital length of stay (p = 0.003 and 0.07, respectively, Kaplan-Meier). The Glasgow Outcome Score-Extended for Pediatrics at hospital discharge and 3, 6, and 12 months after traumatic brain injury and medical complications observed during the acute hospitalization were similar between groups. CONCLUSIONS: Administration of neuromuscular blocking agents was ubiquitous and daily administration of neuromuscular blocking agents was associated with intracranial hypertension but not outcomes-likely indicating that increased injury severity prompted their use. Despite this, neuromuscular blocking agent use was not associated with complications. A different study design-perhaps using randomization or methodologies-of a larger cohort will be required to determine if neuromuscular blocking agent use is helpful after severe traumatic brain injury in children.
RCT Entities:
OBJECTIVE: To evaluate the association between neuromuscular blocking agents and outcome, intracranial pressure, and medical complications in children with severe traumatic brain injury. DESIGN: A secondary analysis of a randomized, controlled trial of therapeutic hypothermia. SETTING: Seventeen hospitals in the United States, Australia, and New Zealand. PATIENTS: Children (< 18 yr) with severe traumatic brain injury. INTERVENTIONS: None for this secondary analysis. MEASUREMENTS AND MAIN RESULTS:Children received neuromuscular blocking agent on the majority of days of the study (69.6%), and the modified Pediatric Intensity Level of Therapy scores (modified by removing neuromuscular blocking agent administration from the score) were increased on days when neuromuscular blocking agents were used (9.67 ± 0.21 vs 5.48 ± 0.26; p < 0.001). Children were stratified into groups based on exposure to neuromuscular blocking agents (group 1 received neuromuscular blocking agents each study day; group 2 did not). Group 1 had increased number of daily intracranial pressure readings more than 20 mm Hg (4.4 ± 1.1 vs 2.4 ± 0.5;p = 0.015) and longer ICU and hospital length of stay (p = 0.003 and 0.07, respectively, Kaplan-Meier). The Glasgow Outcome Score-Extended for Pediatrics at hospital discharge and 3, 6, and 12 months after traumatic brain injury and medical complications observed during the acute hospitalization were similar between groups. CONCLUSIONS: Administration of neuromuscular blocking agents was ubiquitous and daily administration of neuromuscular blocking agents was associated with intracranial hypertension but not outcomes-likely indicating that increased injury severity prompted their use. Despite this, neuromuscular blocking agent use was not associated with complications. A different study design-perhaps using randomization or methodologies-of a larger cohort will be required to determine if neuromuscular blocking agent use is helpful after severe traumatic brain injury in children.
Authors: Patrick M Kochanek; Nancy Carney; P David Adelson; Stephen Ashwal; Michael J Bell; Susan Bratton; Susan Carson; Randall M Chesnut; Jamshid Ghajar; Brahm Goldstein; Gerald A Grant; Niranjan Kissoon; Kimberly Peterson; Nathan R Selden; Robert C Tasker; Karen A Tong; Monica S Vavilala; Mark S Wainwright; Craig R Warden Journal: Pediatr Crit Care Med Date: 2012-01 Impact factor: 3.624
Authors: Laurent Papazian; Jean-Marie Forel; Arnaud Gacouin; Christine Penot-Ragon; Gilles Perrin; Anderson Loundou; Samir Jaber; Jean-Michel Arnal; Didier Perez; Jean-Marie Seghboyan; Jean-Michel Constantin; Pierre Courant; Jean-Yves Lefrant; Claude Guérin; Gwenaël Prat; Sophie Morange; Antoine Roch Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: I R Chambers; L Stobbart; P A Jones; F J Kirkham; M Marsh; A D Mendelow; R A Minns; S Struthers; R C Tasker Journal: Childs Nerv Syst Date: 2004-12-04 Impact factor: 1.475
Authors: M J Fayon; M Tucci; J Lacroix; C A Farrell; M Gauthier; L Lafleur; D Nadeau Journal: Am J Respir Crit Care Med Date: 1997-01 Impact factor: 21.405
Authors: P David Adelson; Susan L Bratton; Nancy A Carney; Randall M Chesnut; Hugo E M du Coudray; Brahm Goldstein; Patrick M Kochanek; Helen C Miller; Michael D Partington; Nathan R Selden; Craig W Warden; David W Wright Journal: Pediatr Crit Care Med Date: 2003-07 Impact factor: 3.624